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1. Introduction 
Systemic lupus erythematosus (SLE) is a prototype of autoimmune diseases with a wide 
range of clinical and laboratory features that involves almost every organ system. The 
prevalence is 52 x 100000 inhabitants in U.S, 21 x 100000 in Canada and 25-91 x 100000 in 
European countries (1). There is an early-onset SLE disease in young women after teenager 
years and a late-onset before the beginning of fifth decade. Women are affected 9 times more 
frequently than men.  
SLE is a complex disease characterized by recurrent relapses and remissions subsequent. 
Nowadays, there is no cure for SLE and this disease can be threatening when major organs 
are affected. 
Unfortunately, SLE can be considered as a disease with a high implication in terms of morbi-
mortality and also, the patients undergoing a great impairment of quality of life, considering 
their potential systemic compromise and/or organ-specific. The patients show decline on 
physical activity as a result of arthritis, undesirable changes in appearance or damage 
produced by long-term use of steroids (often used therapy to treat patients with SLE) such 
as osteoporosis, cataracts, or angina, making it one of diseases with major implications at the 
individual, family, social and economic levels. It affects public health in relation to the 
increase of resources health consumption. 
A better awareness among physicians and patients about this disease, the advent of more 
effective therapies but also more expensive and longer survival of patients with SLE, it has 
led toward an important and better perception of the disease in recent years. The 
socioeconomic data are important as well, since patient survival improves, the accumulation 
of disease and complications treatment-related are crucial in order to appraisal the financial 
burden on both individuals and society. In countries where chronic diseases are prevalent, 
with a growing population and limited economic resources, it is critical a suitable decision-
making on resources to health care. Our current knowledge about the economic impact of 
SLE is very limited and there are only few cost studies conducted by North America and 
Europe, unfortunately. 
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This chapter shows a historical description of approaches to economic evaluation in SLE, 
both at national and international framework and highlighting the main elements that must 
be considered in clinical practice and decisions to avoid increasing the economic burden of 
health care. A non-systematic review of all published literature in English, French and 
Spanish from 1990 to April 2011 was performed using Medline, Pubmed, Cochrane, Lilacs 
and Scielo in peer-reviewed articles, including the Mesh-terms of systemic lupus 
erythematosus, direct costs, indirect and intangible cost, economic impact, disease burden, 
Cost-of-illness (COI) studies, pharmacoeconomics analysis, cost-effectiveness and cost-
utility. It will have three types of approaches: the economic impact of the disease, COI 
studies and finally, a complete pharmacoeconomic assessment. 
2. Overview 
As previously mentioned, the economic evaluations on autoimmune diseases are lack and 
most of them have been carried out on Rheumatoid Arthritis (RA). In the case of SLE has 
virtually been restricted to studies of disease burden and cost-of-illness (COI). The COI 
studies measures the monetary burden that disease entails on society caused by morbidity 
and premature mortality in terms of consumption of health resources and lost of 
productivity. 
In 1967, Rice was the first to outline a methodological framework for calculating single-year 
cost of illness, disability, and death by major category of illness (2). In 1982, Hodgson and 
Meiners created the first guide to study COI (3). The studies’ results are crucial to provide 
informative data to emphasize the extent of the disease problem and highlight the profile of 
patients with SLE. They also have the potential to serve as the basis to a major component in 
economic evaluations such as COI. A valuable COI study included direct, indirect, and 
intangible cost associated with the disease. 
Direct costs represent the opportunity costs of all kind of resources used to treat a disease 
(3). They usually include direct medical costs and direct non-medical costs. The first refer to 
the costs involved to provide treatment, including costs associated with the diagnosis, 
treatment, monitoring, emergency and rehabilitation, while non-medical costs refer to those 
which patients and their families spend on disease but are not medical in nature, including 
transportation costs, cost for household expenditures, and informal care. 
Indirect costs represent lost productivity associated with morbidity, which may be related to 
work or non-work activities. Indirect costs usually represent a large proportion of total costs 
in most of the COI. Indirect costs are usually measured by two methods: Human Capital 
Approach (HCA) and Friction Cost Method (FCT). The results obtained with one and 
another are not comparable and the first estimates tend to be lower than the second. The 
HCA estimates the indirect costs associated with illness and premature death in terms of 
lost productivity (lost wages), thus excluding the costs of pain and suffering, leisure time 
and work on a voluntary. The FCT, which considers the amount people would pay to 
reduce their risk of injury, illness or death, this is subjective and can be difficult to use in 
children and the elderly, due to the complexity of the questions (4). 
Intangible costs refer to patients’ psychological pain of, discomfort, anxiety, depression, 
and stress related to disease or its treatment (5). These are difficult to quantify in 
monetary terms, therefore, they are usually omitted in COI studies or presented as quality 
of life. 
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3. Economic impact of disease 
The first assessment about economic impact of SLE was published in 1994 and it was 
undertaken to assess both the cyclophosphamide (CYC) in intravenous cycles and  
prednisone PO impact for the treatment of severe lupus nephritis (6). The authors 
conducted a hypothetical cohort of patients considering the incidence of severe lupus 
nephritis for U.S. in 1988 (1130 patients). They calculated and compared the costs of 
prednisone as monotherapy vs. prednisone with intravenous CYC, the rate of renal failure 
with each comparative option was also considered, as well as age, gender, and economic 
value of working years gained. The results found that although the costs of combination 
therapy are greater, the analysis shows an overall savings due to reduced need for 
dialysis or kidney transplantation, and the economic value of work capacity won. The 
savings attributable to the costs of patient care were $ 50.8 million and $ 42.3 million 
earned by working capacity. Finally, they conclude that for a period of 10 years, about $ 
93.1 million to year-cohort is saved with the use of combination therapy for treatment of 
severe lupus nephritis. 
Clarke et al (7) presented a study to compare the costs of health care and health status of 
patients with SLE in three countries (Canada, U.S. and UK), which have different health 
systems and financing. 708 patients with SLE were involved in 2 centers for each country 
(Canada 229, UK 268 and U.S. 211), they were evaluated about activity and damage of the 
disease and information on physical and psychological well-being, satisfaction, social 
support, and utilization of health resource. All of the costs were calculated using Canadian 
dollars for 1997. After adjusting for covariate representatives, the Canadian patients, 
compared with the British and Americans, reported a significantly higher health status in 3 
of 8 sub-scales of the SF-36. In general, the annual use of health resources was not 
significantly different, with an average annual cost per patient of CAD $ 4,853, $ 5,285 and $ 
4,760 for Canada, USA and UK, respectively. However, it was found some differences 
within each resource category. Canadians visited more specialists than British, British 
visited more general physician. Canadians and Americans used more emergency services, 
Canadians had higher hospital costs than Americans, and Americans required more 
paraclinical tests and imaging services. 
Zink et al, in 2004, in a comparative study of the disease burden in SLE and rheumatoid 
arthritis (RA), analyzed retrospectively data of 1,248 patients with SLE and 10,068 patients 
with RA, who were seen by rheumatologists in 2001. Significant differences were observed 
in patients who were treated by the rheumatologist; patients with SLE were treated mainly 
with antimalarials (37%), azathioprine (29%), 61% of patients received at least one 
immunosuppressive medication plus steroids. In AR, Methotrexate was the drug most used 
in 63% of patients. A matched analysis showed that SLE patients  with a short duration of 
the disease had pain, functional limitations and general deterioration of health, as well as 
patients with RA; however, in patients with disease duration of more than ten years, 
deterioration in health status, was greater in patients with RA. The authors report that in the 
early stages of both diseases, related costs of health care and burden of disease are similar, 
but in chronic disease, RA significantly increased costs in relation to pain, poor overall 
health state and disease activity, as well as greater severity classified by the specialist, 
suggesting a better long-term prognosis in SLE in the areas observed. Regarding the current 
treatment, showed an impact when the two diseases are treated by rheumatologists since 
onset-disease (8). 
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The same author Clarke et al in 2004, published an interesting study which sought to 
determine whether the consumption of health resources are correlated with outcome in the 
health status of SLE patients in three developed countries: USA, UK and Canada. 715 
patients were surveyed semi-annually (Canada 231, U.S. 269, and UK 215) to determine the 
utilization of health resources and outcomes in health status. In 2002, the average 
cumulative costs per patient over 4 years were CAD $ 15,845, $ 20,244 and $ 17,647 for 
Canada, USA, and UK respectively, they experimented similar outcomes in health. After 
adjusting differences in input data, on average, Canadian and British patients utilized 20% 
and 13% less resources than American patients, respectively. The authors comment that 
despite incurring higher health expenditure, American patients did not experiment great 
results in health (9). 
Grootscholten C et al in 2007 (10) developed a prospective randomized controlled study to 
measure the effect of treatment with CYC pulses or azathioprine (AZA) plus 
methylprednisolone (MP) for a period of 24 months, evaluating health-related quality of  
life (HRQOL) of patients with Proliferative Lupus Nephritis (PLN). This study measured 
HRQOL and disease activity at the beginning and after at 12 and 24 months. It was 
applied the Visual Analog Scale (VAS), SF-36, and a questionnaire to measure activity 
disease (SLEDAI). The impact of treatment was measured 24 months later and disease 
activity was measured with the SLEDAI and physician's VAS. They included 87 patients, 
and only 47 of them completed the questionnaires. HRQOL improved significantly with 
treatment, particularly during the first year; however, there were no significant 
differences between the group treated with CYC and AZA/MP; on the other hand, there 
was a strong favorability in the group treated with AZA/MP when SF-36 was applied. 
The average reported in the impact on treatment within 24 months was significantly 
higher in the group treated with CYC. HRQOL was not correlated neither with the 
SLEDAI nor the physician's VAD. This study concluded that treatment of PLN patients 
with immunosuppressive drugs and corticosteroid improve QOL, particularly in the first 
year and this effect was sustained in the second year of treatment. But because such a 
small sample and lack of differences in HRQOL between CYC and AZA/MP groups, 
these results should be interpreted with caution. The CYC-treated group showed a high 
impact on the budget. Data from this study do not support the use of AZA/MP as first 
line treatment for PLN, but this could be an alternative for women who wish to become 
pregnant. They propose future studies with Mycophenolate Mofetil and low-dose CYC as 
therapeutic alternatives in these patients. 
An interesting evaluation performed by Campbell et al (11), involved the impact of SLE on 
working capacity. This study evaluated the status of work (such as job loss, changes in the 
amount worked) and predictors of job-loss in patients with SLE. The patients with onset-
disease recently diagnosed were included, followed-up at least two years and matched by 
sex and age. Patients were followed-up for an average of 4 years from diagnosis. Work 
history was obtained through a personal interview during the recruitment and through 
telephone interviews to follow-up. The authors highlight an important difference for 
working withdrawals during follow-up between SLE patients and controls (26 vs. 9%, p 
<0.0001). 92 of SLE patients showed that the cause of abandonment was related to their 
health status. Patients with SLE who had arthritis were three times more likely to quit their 
jobs due to changes in health compared with those who did not have arthritis (adjusted OR 
3.3 IC95% 1.1 to 8.8). Finally, an association with the presence of pleuritis was founded 
(adjusted OR 2.3 95% 1.1 to 4.6). 
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4. Cost-of-illness studies in SLE 
Until the last century the most studies in SLE tended to ignore the evaluations that included 
both loss of productivity in work activities and diary live activities and they focus only on 
direct costs such as number of hospitalizations and health status measures. 
In 1993, Clarke et al (12) published the first assessment which identified the direct and 
indirect costs of 164 patients with SLE who entered to the Lupus register of Montreal 
General Hospital between January 1977 and January 1990; they compared the costs with the 
general population of Quebec and also determined the predictors of costs. The estimated 
cost was $ 13,094 CAD in 1990, of which 54% represent indirect costs ($ 7,071). In average, 
SLE hospitalizations were 4 times more frequent than general population of Quebec 
(matched by gender and age), and the number of outpatient visits were twice than which 
represented by the general population. The best predictors of direct costs were high levels of 
creatinine and poor level of physical performance. A poor level of well-being, a combination 
of education level and employment status, and poor social support were the best predictors 
for indirect costs. 
Clarke et al, in 2000, carried out an indirect costs analysis and it was calculated as a result of 
decreased productivity in women with SLE. Indirect costs incurred by women with SLE 
were calculated obtaining the costs from labour and non-labour activities decreased. Six 
hundred forty-eight women with SLE reported their employment status and time lost for 
themselves and their employers as well as non-labour activities over a period of 6 months. 
The average annual indirect costs ranged from $ 1,424 to $ 22,604 CAD to 1997, and they 
depended on the value assigned to the labour market and non-labour activities (13).  
Sutcliffe et al, in 2001, determined the direct costs, indirect costs and predictors in patients 
with SLE. 105 patients with SLE completed the questionnaires about using of health services 
and employment history. A multiple regression analysis determined predictors of costs. 
Direct, indirect and total costs were the depending variables, and demographic data, health 
status, disease activity, target organ damage, social support and satisfaction with care were 
used as predictors. The average total annual cost per patient was £7,913. Direct costs were a 
third of the total costs and indirect costs represented 2/3 of total cost. A good level of 
education, greater disease activity and reduced physical function were associated with 
increased direct, indirect and total costs. The major direct costs are also associated with 
greater impairment and younger age of onset-disease. The authors conclude that SLE has a 
considerable impact on the health system and society. Improving disease activity and 
physical health, as well as the prevention of organ damage can significantly reduce costs in 
SLE (14). 
In 2001, Clarke et al compared the direct and indirect costs of care for SLE patients in 
Canada, USA and UK. In general, the cost of care of patients with SLE is cheaper in UK, 
because of fewer resources used and number of hospitalizations reduced; however, a 
significant statistical difference were not found. Additionally, indirect costs of SLE 
increased dramatically the cost of the disease was another finding. When indirect costs 
included only job loss, the cost per patient was $ 10,000 a year and if it is considered 
household task, the cost increased to $ 22,000 (4 times the annual direct costs) (15). 
A comparative assessment of costs of rheumatic diseases was made in Germany. In this 
study, Li et al, in 2006 (16) estimated and compared direct and indirect costs of illness in 
Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), Psoriatic Artritits (PA) and SLE; 
they evaluated the gender, disease duration and functional status effect on various costs 
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domains. Data were extracted from the German national data set from 1993. The costs 
were calculated for each patient for the last twelve months prior to recruitment date. The 
direct costs were € 4,737 per year in RA, € 3,676 in EA, € 3,156 in PA and € 3,191 SLE. 
Costs increased with duration of disease and they were heavily dependent on functional 
status. Compared with RA, drug costs in SLE were less than half; patients with AS and PA 
had less treatment costs in hospitalized patients for acute complications than those with 
RA and SLE. Calculating the indirect costs were higher in SLE (€ 11.220), followed by AR 
(€ 10,901). 
Panopalis et al in 2007 compared cumulative indirect costs over 4 years in the care of 
patients with SLE in the U.S., Canada and UK. They surveyed a total of 715 patients with 
SLE (269 U.S., 231 in Canada and 215 in UK) at baseline and semi-annually, during four 
years (May 1999-October 2001). Participants completed questionnaires about the use of 
health resources, employment status, lost work days and lost time spent by caregivers on 
administrative procedures to access health services and / or daily household tasks. 
Annually, the patients reported surveys about quality of life, social support, and satisfaction 
with care. This study is a cross-national comparison of indirect costs in SLE, this is valuable 
information due to the difficulty of measuring indirect costs and the importance they 
represent because they contribute to a high percentage of total costs in SLE. The authors 
found that indirect costs accounted for 74% of total costs, being significantly higher in 
American patients, and this increase corresponded to the additional labour hours that 
patients would have worked, if they had not been ill. The authors concluded that indirect 
costs represent a significant proportion of total costs in the care of patients with SLE and 
they suggest that among SLE economic evaluations should include indirect costs attributed 
to productivity lost (17). 
Clarke et al in 2008 compared the costs and quality of life among patients with SLE with and 
without kidney damage; the authors evaluated 715 patients through a semi-annualized 
interview during four years, in order to determine the use of medical services, loss of 
productivity and annually the quality of life. The accumulated direct and indirect costs and 
quality of life (analyzed through the SF-36) were compared between SLE patients with and 
without renal damage, through of Damage Index for SLE from System Lupus International 
Collaborating Clinics/ACR. On this scale was considered 0, one patient without renal 
impairment; 1, with a glomerular filtration rate or creatinine clearance less than 50%; 2, 
proteinuria greater than 3.5 g; or 3, end-stage kidney disease. Each criterion should be 
present in at least six months to be considered as kidney damage. Cumulative average direct 
costs per patient in 2006 were CAD $ 20,337, $ 27,869, $ 51,191 and $ 99,544 for stages 0-3 
respectively. For every increased unit on renal damage, it was associated with an increase 
on average of 24% on direct costs through regression analysis. In addition, patients with 
end-stage renal disease incurred 103 % more than those without kidney damage. 
Cumulative indirect costs, lost productivity and the annual change in SF-36 did not show 
difference between patients (18). 
Panopolis et al estimated health care costs and costs associated with changes in labour 
productivity among people with SLE in the U.S. The data were derived from the University 
of California. Participants provided information on the use of health resources and 
employment. Estimations about costs were derived for both of health care costs and costs 
related to changes in labour productivity. Direct health care costs included hospitalization 
costs, emergency service use, doctor visits, ambulatory surgery, dialysis and drugs. 
Productivity costs were calculated by measuring the decrease of productive working hours 
www.intechopen.com
 
Economic Evaluations in Systemic Lupus Erythematosus 19 
since onset SLE disease, although these estimates were also compared with general data 
from U.S. population. For all participants, the average annual direct costs were $ 12,643 
(2004, U.S. dollars). The average annual costs of the productivity in working-age people (> 
or = 18 and <65 years) were $ 8,659. The average total annual costs for working-age were $ 
20,924. The increase of disease activity, a longer duration of illness, and mental and physical 
health impairment were significant predictors of increase in direct costs, because to changes 
in labour productivity. The authors concluded that the direct costs and costs associated with 
changes in labour productivity are important and they represent an important contribution 
to the total costs associated with SLE (19). 
Carls et al in 2009 estimated the medical costs related to the productivity of SLE and Lupus 
Nephritis (LN) in a population of employees between 2000 and 2004. These costs were 
compared with other chronic diseases costs. The average annual medical expenses and the 
short-term costs given by disabilities for patients with SLE were US (2005) $ 12,238 and $ 
1,184 respectively, in comparison to control diseases. The average medical expenses in LN 
patients were $ 46,862 higher than the controls. Compared with other chronic health 
conditions that occurred in this group of employees, SLE / LN was the most expensive 
condition. The authors conclude that SLE, particularly with LN, is associated with 
significant costs. The treatment that lead to manage earlier and effective to the patients with 
SLE, it can result in an important decrease of costs, if they are started on time in order to 
reduce complications that generate more costs of care (20). 
In another study, Zhu T, et al in 2009 determined the direct and indirect costs for patients 
with SLE in a rheumatology center in Hong Kong. They determined the relationship 
between Neuropsychiatric SLE (NP-SLE) and costs of the disease through a retrospective 
cross-sectional, non-randomized study. All participants completed questionnaires on 
demographic data, employment status and personal expenses. The consumption of health 
resources was registered in a file. 
The onset of NP-SLE since the beginning of SLE was determined using the 1999 ACR 
criteria. Costs of the disease among patients with and without NP-SLE were compared by 
the Mann-Whitney test and the predictors of costs were obtained by a multiple linear 
regression analysis. 306 Chinese patients were recruited with an average age of 41 years 
and the disease duration of 9.6 years. There were a total of 108 events of NP-SLE in 83 
patients. The most common manifestations were seizures and cardiovascular disease. The 
total annual costs were US $ 13,307 per patient. Direct costs dominated total costs, and 
hospital care costs accounted for 52% of direct costs. Patients with NP-SLE incurred in 
direct and indirect costs significantly higher when they were compared to those without 
NP-SLE. The number of events NP-SLE was an independent variable associated with 
direct and indirect costs. So, the implementation of an intervention in the prevention of 
organ damage, especially in neuropsychiatric manifestations may reduce the costs of 
patients with SLE (21). 
In another study, in 2009, Li et al estimated the direct medical costs to long-term of SLE 
patients and a subgroup of patients with SLE and LN. Active SLE patients of a large 
database and during this monitoring period, 2298 patients and a control group between 
1999 and 2005 were included. The average annual medical costs for patients with SLE were 
higher than in the control group in the first year (US $ 16,089 vs. $ 6,831, respectively). Costs 
decreased slightly in the second year but increased 16% annually for five years to $ 23,860. 
LN patients (n = 489) were USD $ 13,228 - $ 34,907 higher than the control patients and the 
hospitalization rate in the subgroup with LN was 0.6 to one per capita, which was double 
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compared with SLE patients without LN, and 3 to 4 times higher than the control group. 
This study concluded that SLE is an expensive condition, and medical expenses increased 
steadily over time, particularly for patients with LN SLE (22). 
Zhu T et al in 2009 (23) assessed the direct and indirect costs of flare SLE patients and non-
flare SLE patients from a social perspective in order to investigate the severity impact and 
the direct and indirect costs from flare clinical manifestations. The authors defined as 
activity 3 points or more in SELENA – SLEDAI, and 4 points or more in the BILAG, being 
this between 0 and 105 (maximum activity). Mild or moderate relapse was defined as one or 
more of the following:  
1. Change in SELENA - SLEDAI of three points.  
2. Worsening discoid lesions or new lesions, photosensitivity, cutaneous vasculitis, 
nasopharyngeal ulcers, pleuritis, pericarditis, arthritis or fever. 
3. Increase of prednisolone dose without exceeding 0.5 mg / kg / day.  
4. Necessity of adding or increasing NSAID or hydroxychloroquine.  
While severe relapse was defined as:  
1. Change in SELENA-SLEDAI twelve-points.  
2. New or worsening vasculitis, nephritis, myositis, thrombocytopenia less than 60,000 or 
anemia with Hb less than 7, requiring increase prednisolone dose to 0.5 mg / kg / day  
3. Use of new immunosuppressive agents.  
4. Hospitalization for SLE.  
A validated physical index consists of 41 items in 12 organs frequently used to measure the 
accumulated damage was used to measure damage (Systemic Damage Index -SDI). Damage 
was defined as any irreversible change occurred since the onset-disease of SLE which is 
observed for at least 6 months. The total SDI scores ranging from 0 to 49. They also defined 
each of the activities according to the organ involved. 
This was a retrospective study of the disease costs; 306 Chinese patients between 18 and 65 
with SLE were included and recruited between January 2006 and August 2007. Participants 
completed questionnaires on demographic data, employment status, and out-of-pocket 
expenses. The consumption of health resources was recorded in a questionnaire that 
patients self-reported. Total number of flares and the organs affected in the last 12 months 
were recorded. The authors found that patients with flare were younger with a shorter 
duration of illness and a higher disease activity at the evaluation time. The overall incidence 
of lupus flares was 0.24 episodes per patient-year. Patients with flares used more frequently 
health resources and increased significantly the direct and indirect annual costs. 
The total average costs per patient-year were two times higher for patients with flare (USD 
2006 $ 22,580 versus $ 10,870, p <0.0005). A multiple regression analysis showed that the 
number of relapse was an independent variable that leads to increase direct costs. Patients 
with renal / neuropsychiatric flare had higher direct costs compared with those with single-
organ flare. The main conclusion of this study was that patients with flare incurred higher 
direct and indirect costs compared with those without crisis. The main organs affected by 
flares were renal and neuropsychiatric whose patients incurred higher costs for the disease 
than flares of other organs. The treatments that control effectively the disease activity and 
prevent relapses, especially the flare in vital organs, may reduce the high costs associated 
with relapse in SLE. 
In Colombia, Quintana et al (24) conducted a study to determine the direct costs of health 
care for the first year of treatment for LN, based on the classification system of the 
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International Society of Nephrology / renal Pathology Society (ISN / RPS) (25); it is the first 
assessment that discriminates on type of renal histopathologic injury, finding a cost of $ 
1,160 (USD, 2009) for LN type I and II; the type III and V share the same costs of $ 3,498 
using the EUROLUPUS scheme in induction and maintenance with azathioprine (AZA). In 
case of use of mycophenolate (MMF), the costs increased to $ 13,646 for type III LN and $ 
14,161 for the LN type V. In type IV the cost was $ 3,499 using the EUROLUPUS scheme and 
maintenance with AZA. The costs amount to $ 14,163 if is used MMF for induction and 
maintenance. 
5. Complete pharmacoeconomic evaluations 
Wilson et al in 2007 conducted a study that sought to determine whether the results of LN 
treatment with MMF, represented a positive impact on quality of life (QoL) and a better use 
of resources. The authors created a simulation model to estimate the costs of quality-
adjusted life year (QALY) of a LN patient treated with intravenous Cyclophosphamide 
(CYC) or with MMF for an adjusted period of six months. The efficiency, quality of life, 
resource uses and cost data were obtained from literature and standard databases and 
where necessary, data were supplemented by expert opinion. The model predicts that the 
use of MMF improved the quality of life compared with intravenous CYC. In addition, 
MMF is less expensive than CYC, at a cost of £ 1.600 (€ 2,400, $ 3,100), a lower cost based on 
2005 prices the National Health System. The additional price in the application of 
intravenous of CYC was the main determinant of this variation. The sensitivity analysis 
shows a 81% probability that the use of MMF is more cost effective compared with 
intravenous CYC, with a willingness to pay £ 30,000 (€ 44,700, $ 58,500) per QALY gained. 
The authors of this study concluded that the use of MMF represented an improvement in 
the quality of life, and is less expensive than intravenous CYC as induction therapy for LN 
(26). 
6. Conclusions 
SLE costs are primarily determined by factors related to disease state such as: duration, 
disease activity, damage, and also the state of physical and mental health of patients which 
are influenced by the disease progression and the accumulated damage. The compromise of 
major organs such as nephritis and neuropsychiatric lupus, and relapses are also known 
factors associated with increased direct and indirect costs, independent of demographic 
factors. It is well-known that interventions that lead to the control of disease activity, 
prevent relapses, and delay the progression of the disease, can potentially save large 
amounts of costs attributable to the damage and the compromise of target-organ. 
In the studies reviewed in this chapter were found large discrepancies in both direct and 
indirect costs, a situation that cannot simply be explained by demographic and clinical 
differences, across different populations. These discrepancies can be attributed to the 
absence of defined guidelines for cost-effectiveness analysis. It should be noted that there 
are great differences in the context of the costs, methods of costing, the health system, and 
practice patterns through studies. It should also be considered, the studies reviewed are 
derived from several different types of studies from different countries over a period of at 
least 16 years. Changes in the state of knowledge about disease, medical technology and 
practice patterns can have substantial influence on the estimate of the costs. It is important 
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to set out more studies to highlight the magnitude of the problem of SLE to society and 
people in different countries, and these studies should have innovative designs that will be 
able to resolve methodological lack found in some studies. 
Nowadays, there are new therapies specifically routed to the immune system (Belimumab); 
these therapies can control the activity of the disease and prevent exacerbations of target 
organ in SLE. Their costs are probably much higher than conventional therapies. Given the 
substantial costs associated with SLE, it is expected that the potential benefits of these 
therapies offset their costs and new economic evaluations will give more information about 
the properties. 
7. Key point section 
1. SLE costs are related to health statement which is influenced by the disease progression 
and the accumulated damage. 
2. Direct and indirect costs are influenced mainly by major organs compromise such as 
nephritis and neuropsychiatric lupus and flares. 
3. Save large amounts of costs can achieve through the control of disease activity, prevent 
relapses, and delay the progression of the disease. 
4. There are discrepancies in the results of both direct and indirect cost studies which can 
be attributed to the absence of defined guidelines for cost-effectiveness analysis 
5. New studies are necessaries to innovate designs in order to resolve methodological lack 
found in before studies, including the new therapies like Belimumab. 
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